Chimerix appoints Allen Melemed as CMO

Chimerix (NASDAQ:CMRX) appointed Dr. Allen Melemed as its CMO.

Dr. Melemed was most recently a distinguished medical fellow and senior director of North American regulatory affairs oncology at Eli Lilly (NYSE:LLY). He spent more than 20 years at the company, dedicated to the clinical development and approval of oncology medicines across a broad range of tumor types.

“We look forward to leveraging [Dr. Melemed’s] considerable clinical and regulatory experience as a distinguished pharmaceutical executive,” Mike Sherman, Chimerix’s CEO, said in a statement.

“His vast experience bringing oncology therapeutics through development and approval across multiple modalities will be invaluable as we initiate our dociparstat sodium Phase 3 trial in first-line acute myeloid leukemia, our ongoing Phase 2/3 trial to combat acute lung injury in COVID-19 patients, and finalize our rolling NDA for brincidofovir as a medical countermeasure for smallpox,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.